Despite important advances in expanding the physician knowledge base in the field of psoriasis, substantial deficits remain in the understanding of psoriasis and its treatment, necessitating further research in many areas.
The most important gaps in research and suggestions for studies that should be performed to address these deficits will be discussed in “Research Gaps in Psoriasis: Opportunities for Future Studies and Development of New Outcome Measures for Clinical Trials” led by Alice B. Gottlieb, MD, PhD. The session will be presented from 3:30 to 5:30 p.m. Friday in Room 147B.
Among the topics covered, will be the efforts of the International Dermatology Outcomes Measures (IDEOM) Committee to develop outcome measures using the Delphi method that accurately and reliably measure the impact of treatments on patients’ disease severity and quality of life.
IDEOM is working on the psoriasis outcome measures, but any measure will have to be approved by the FDA. Kendall Marcus, MD, is the new director of the dermatology department at the FDA and will give the insights on what the FDA is looking for in dermatology outcome measures. Kristina Patrice Callis-Duffin, MD, will talk about results of IDEOM using DELPHI process for psoriasis outcomes.
Joel M. Gelfand, MD, MSCE, will discuss key research gaps in psoriasis and psoriatic arthritis, and opportunities for future studies. Joseph Merola, MD, MSc, will talk about intertriginous disease outcome measures. A panel discussion with all faculty will take place after the presentaitons. The session is open admission to eligible categories, no tuition or ticket is required.